Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Studies in focus

Interleukin-31 as a clinical target in prurigo nodularis.

    • Dermatology and venereology
    • Education
    • RX
    • Studies
  • 3 minute read

For the treatment of prurigo nodularis, there are rather few approved therapeutic options available today. There is a need for new effective and well-tolerated treatment options. The use of the IL31 inhibitor nemolizumab is currently being clinically tested in various pruriginous skin diseases, including prurigo nodularis. The balance so far is positive.

Prurigo nodularis is a rare, poorly studied chronic skin disease characterized by hyperkeratotic severely pruritic papules, often resulting in an itch-scratch cycle (review 1) . As a consequence, sleep disturbances and psychological complaints may develop [1]. Mostly people over 50 years of age are affected by this distressing skin disease. Apart from corticosteroids and topical creams, there are currently no treatment options approved for the indication prurigo nodularis, and new therapeutic options would be desirable.

 

 

Nemolizumab as a beacon of hope

In a phase II clinical trial published in the New England Journal of Medicine last year, nemolizumab was shown to be highly effective in reducing pruritus in patients with moderate to severe prurigo nodularis and severe pruritus [2]. In addition to prurigo nodularis, the use of this anti-IL31 antibody is also being investigated with respect to other skin diseases associated with pruritus, including atopic dermatitis [3]. IL31, like IL4 and IL13, is a cytokine produced by Th2 cells and plays an important pathophysiological role in various pruriginous skin diseases [4]. Nemolizumab is currently the only anti-IL31 antibody that has successfully completed large advanced clinical trials.

In a 12-week randomized double-blind placebo-controlled phase II trial, 70 study participants with moderate to severe prurigo nodularis and at least 20 or more nodules or severe prurigo nodularis, defined as an average daily pruritus score of 7/10 (10 = maximum imaginable pruritus intensity), were randomized to the two study arms, nemolizumab vs. placebo. Subjects in the verum condition received three subcutaneous injections of nemolizumab 0.5 mg/kg body weight at baseline, week 4, and week 8.

 

 

Rapid onset of symptom reduction

Nemolizumab-treated study participants (n=34) experienced a 53.0% reduction in itch* 4 weeks after baseline compared to a 20.2% reduction in the placebo group (n=36) (p<0.001). Thus, the study met the primary endpoint. After 12 weeks, the nemolizumab group showed a reduction in the number of lesions by an average of 12.6 versus 6.1 in the placebo group. At the last follow-up measurement at week 18 after baseline, 10 weeks after administration of the last dose of nemolizumab, the mean reduction in the number of lesions was 13.3 in the treatment arm and 7.5 in the placebo arm. In general, nemolizumab was well tolerated. Gastrointestinal symptoms, abdominal pain, and diarrhea were reported by 21% on nemolizumab and 14% on placebo, and for musculoskeletal symptoms, these proportions were 18% and 14%, respectively.

* Pruritus Numerical Rating Scale (Pruritus-NRS)

 

Overall, the conclusion is positive. While the study authors had expected the anti-IL31 antibody to prove effective in reducing symptoms of prurigo nodularis, they were surprised by the rapid onset of efficacy of nemolizumab. Currently, a phase III trial is ongoing to evaluate the efficacy and safety of nemolizumab in patients with prurigo nodularis ([5] ClinicalTrials.gov, NCT04501679).

 

Literature:

  1. Zeidler C, et al: Chronic prurigo of nodular type: a review. Acta Derm Venereol 2018; 98: 173-179.
  2. Ständer S, et al: Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 2020; 382: 706-716.
  3. Kabashima K, Irie H: Interleukin-31 as a Clinical Target for Pruritus Treatment. Front Med (Lausanne) 2021; 8: 638325.
  4. Bieber T, et al: Novel therapies based on the pathophysiology of atopic dermatitis. JDDG 2019 17; 11: 1150-1163.
  5. ClinicalTrials.gov, NCT04501679 (last accessed 30/30/2021).
  6. Sonkoly E, et al: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-417.

 

DERMATOLOGY PRACTICE 2021; 31(2): 24

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Interleukin
  • prurigo
Previous Article
  • Type 2 diabetes

Treatment success thanks to individual therapy goals

  • Congress Reports
  • Endocrinology and Diabetology
  • General Internal Medicine
  • RX
View Post
Next Article
  • Breast Cancer

Metastatic pathways in focus

  • Education
  • Gynecology
  • Oncology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
View Post
  • 4 min
  • Oral JAK-i in atopic dermatitis

Benefits and risks: What does the current data say?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 17 min
  • Sleep-wake disorders in pneumology practice

Patience, knowledge and persistence in therapy

    • CME continuing education
    • General Internal Medicine
    • Neurology
    • Pneumology
    • RX
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • RX
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 9 min
  • Oxidative stress and neurodegeneration

Insights and therapeutic strategies for Parkinson’s disease

    • Education
    • Neurology
    • Phytotherapy
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.